Can aspirin stop liver cancer in hepatitis B patients?

October 20, 2017

(HealthDay)—Daily aspirin may reduce the risk of liver cancer for people with hepatitis B infection, a new study suggests.

Hepatitis B virus attacks the and can cause cirrhosis and liver cancer. Previous research suggests daily low-dose aspirin therapy may prevent cancer, but there is little clinical evidence on whether regular aspirin use can prevent liver cancer in people with hepatitis B.

Researchers from Taiwan analyzed data from close to 205,000 patients with chronic hepatitis B. They found that those on daily aspirin were much less likely to develop liver cancer over five years than those who did not take aspirin.

It's important to note, however, that the study only found these associations, but did not establish a cause-and-effect link.

The findings are scheduled to be presented Monday at an American Association for the Study of Liver Diseases meeting, in Washington, D.C.

About 240 million people worldwide have chronic hepatitis B, according to the association.

While antiviral medicines can significantly reduce liver risk in people with the hepatitis B virus (HBV), they don't eliminate it and are not appropriate for everyone, said lead investigator Dr. Teng-Yu Lee.

Lee is a researcher in the department of gastroenterology at Taichung Veterans General Hospital.

"For effectively preventing HBV-related , the findings of this study may help hepatologists treat patients with chronic HBV infection in the future, particularly for those who are not indicated for antiviral therapy. We are pursuing prospective investigations for further confirming the findings," Lee said in a meeting news release.

Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal.

Explore further: Successful treatment for hepatitis C reduces risk of liver cancer later in veterans

More information: The U.S. Centers for Disease Control and Prevention has more on hepatitis B.

Related Stories

Successful treatment for hepatitis C reduces risk of liver cancer later in veterans

April 25, 2016
A new study by researchers at Baylor College of Medicine found that treatment and cure of chronic hepatitis C reduce the risk of hepatocellular carcinoma (HCC), especially if given early, before cirrhosis develops, and while ...

Antiviral therapy can prevent liver cancer in chronic hepatitis B patients

June 23, 2014
One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. Two new studies appearing in the June issue of Gastroenterology ...

Risk of liver cancer from hepatitis B persists even after clearing the virus

April 22, 2016
Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection ...

Mavyret approved for hepatitis C

August 4, 2017
(HealthDay) —Mavyret (glecaprevir and pibrentasvir) has been approved by the U.S. Food and Drug Administration to treat adults with certain types of chronic hepatitis C virus (HCV).

Antiviral drug prevents recurrence of hepatitis C in liver transplant patients

January 10, 2017
Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II ...

Antiviral therapy may prevent liver cancer in hepatitis B patients

June 9, 2014
Researchers have found that antiviral therapy may be successful in preventing hepatitis B virus from developing into the most common form of liver cancer, hepatocellular carcinoma (HCC).

Recommended for you

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.